BioSpace News Archive

Close-up Of Businessperson Shaking Hands With Robot

AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch

Anthropic in October last year iterated its Claude AI model to better cater to biopharma purposes. Sanofi, Novo Nordisk, AbbVie and others already use Claude in their operations.

April 6, 2026

·

2 min read

·

Tristan Manalac

Stethoscope with compass isolated on orange background. 3d illustration

Regulatory

Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA Direction

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency’s future regulatory decision-making, analysts say, with implications stretching well beyond one company.

April 6, 2026

·

5 min read

·

Ben Hargreaves

Big fish eats small, takeover of the company. Art collage.

Mergers & acquisitions

Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of Vykat XR, approved last year for extreme hunger in patients with Prader-Willi syndrome.

April 6, 2026

·

2 min read

·

Tristan Manalac

Two hands locked in a handshake cut by a pair of scissors, symbolizing a severed relationship or partnership. Black and white collage illustration on paper textured background

Neurodegenerative diseases

Takeda Breaks Up With Denali, Dumps Dementia Drug

Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was previously discontinued after an FDA hold and disappointing early data.

April 6, 2026

·

2 min read

·

Tristan Manalac

Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.

Pipeline

Pharma Pipeline Stalls for First Time in Decades: Citeline

Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.

April 6, 2026

·

2 min read

·

Tristan Manalac

Doubtful person, hands on hips, choosing the way as multiple arrows on the road showing a mess of different directions. Choosing the correct pathway, difficult decision concept, confusion symbol.

FDA

FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls

While recent FDA guidance speaks to the agency’s support of innovative trial designs—including the use of external controls—the application of this flexibility appears to be inconsistent. One former regulator says the situation is more nuanced.

April 6, 2026

·

6 min read

·

Heather McKenzie

IN PARTNERSHIP WITH API

Lean Derisking: Smart Ways to Cross Drug Development’s “Valley of Death”

Nobel laureate Sir Michael Houghton and colleagues at Applied Pharmaceutical Innovation (API) outline how rigorous early testing, smart IP and regulatory planning, and scalable CMC choices can help founders reach first-in-human faster.

April 6, 2026

·

4 min read

·

Jennifer C. Smith-Parker

Press Releases

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

April 6, 2026

·

5 min read

Press Releases

Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform